Inquiry Basket
Nicardipine Hydrochloride - CAS 54527-84-3 Catalog number: BADC-00300
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Nicardipine is a calcium channel blocker used to treat high blood pressure and angina.
Category
ADCs Cytotoxin
Product Name
Nicardipine Hydrochloride
CAS
54527-84-3
Catalog Number
BADC-00300
Molecular Formula
C26H29N3O6.HCl
Molecular Weight
515.99
Ordering Information
| Catalog Number | Size | Price | Quantity |
|---|---|---|---|
| BADC-00300 | 25 g | $248 |
Description
Nicardipine is a calcium channel blocker used to treat high blood pressure and angina.
Synonyms
RS-69216; RS 69216; RS69216; YC-93; YC 93; YC93.
IUPAC Name
5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC.Cl
InChI
InChI=1S/C26H29N3O6.ClH/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19;/h5-12,15,24,27H,13-14,16H2,1-4H3;1H
InChIKey
AIKVCUNQWYTVTO-UHFFFAOYSA-N
Solubility
Chloroform,methanol (1:1), not in water
Melting Point
168-170 °C.
In Vitro
The permeation flux of nicardipine hydrochloride across rat epidermis was increased markedly by the addition of limonene to the HPC gels. A maximum flux was observed (246 +/- 1 micrograms/cm2/h) with an enhancement ratio of about 8 when limonene was incorporated at a concentration of 4% w/w. However, there was no further increase in the permeability of nicardipine hydrochloride beyond 4% w/w of limonene.
Clinical Trial Information
| NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
|---|---|---|---|---|---|
| NCT00325793 | Hypertension | Phase 4 | 2006-05-15 | OSF Healthcare System | Unknown Verified May 2006 by OSF Healthcare System. Recruitment status was Recruiting |
| NCT01810302 | Cerebral Vasospasm | Phase 2 | 2014-08-29 | University of Florida | Terminated (Unable to secure drug.) |
| NCT00508118 | Aortic Aneurysm, Thoracic | Phase 2 | 2014-08-01 | Duke University | Terminated (3/7 subjects experienced hypotension. Study was terminated.) |
| NCT00409253 | Hypertension During Pre-Eclampsia | Phase 3 | 2009-02-25 | University Hospital, Strasbourg, France | Unknown Verified February 2009 by University Hospital, Strasbourg, France. Recruitment status was Recruiting |
| NCT01951950 | Brain Tumors | Phase 1 | 2014-08-29 | Northwestern University | Completed |
Application
ADCs Cytotoxin
Appearance
light yellow solid
Purity
>98% (HPLC).
Shipping
Room temperature, or blue ice upon request.
Storage
Stable in dry state, store at + 4 °C, in dark place.
Pictograms
Acute Toxic
Signal Word
Danger
1.Pre-surgical regional blocks in orthognathic surgery: prospective study evaluating their influence on the intraoperative use of anaesthetics and blood pressure control.
Chen YA1, Rivera-Serrano CM1, Chen C2, Chen YR3. Int J Oral Maxillofac Surg. 2016 Jan 19. pii: S0901-5027(15)01332-6. doi: 10.1016/j.ijom.2015.09.014. [Epub ahead of print]
In orthognathic surgery, maxillary (CNV2) and mandibular (CNV3) divisions of the trigeminal nerve can be blocked successfully prior to surgery. In this study, it was hypothesized that regional blocks (nerve block over a particular region: bilateral CNV2 and CNV3 divisions of the trigeminal nerve) would decrease the total requirement for intraoperative anaesthetic agents and facilitate the process of hypotensive anaesthesia. Local anaesthesia containing 1/100,000 epinephrine and 10ml 0.5% levobupivacaine was injected into the planned incisions in 50 patients. Twenty-five patients (group A) underwent orthognathic surgery without regional blocks and another 25 patients (group B) underwent surgery with regional blocks. The anaesthetic protocol was the same in both groups and administered by a single anaesthesiologist. The mean arterial pressure was recorded at several points throughout the operation, as well as all the medications used. The blood loss and the amounts of medications administered were lower in group B than in group A.
2.Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Wang YC1, Hsieh TC, Chou CL, Wu JL, Fang TC. Medicine (Baltimore). 2016 Jan;95(2):e2487. doi: 10.1097/MD.0000000000002487.
Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Inhibitors of CYP3A4 including some calcium channel blockers (CCBs) might increase statin blood concentration, owing to drug-drug interactions. Risk of adverse events such as acute kidney injury might occur following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.This was a population-based cohort study. The study analyzed data of patients treated between 1997 and 2011, retrieved from Taiwan's National Health Insurance database. We enrolled 32,801 patients who received coprescription of statins and CCBs that inhibit CYP3A4 (amlodipine, diltiazem, felodipine nicardipine, nifedipine, and verapamil). These patients were divided into 2 groups, according to whether they had received CYP3A4-metabolized statins (lovastatin, simvastatin, and atorvastatin) or non-CYP3A4-metabolized statins (fluvastatin, rosuvastatin, and pitavastatin).
3.Nicardipine for Hypertension Following Aortic Coarctectomy or Superior Cavopulmonary Anastomosis.
Mastropietro CW1, Arango Uribe D2. World J Pediatr Congenit Heart Surg. 2016 Jan;7(1):32-5. doi: 10.1177/2150135115608815.
BACKGROUND: Literature on the use of nicardipine, a dihydropyridine calcium channel antagonist, in children recovering from cardiac surgery is sparse and, to our knowledge, nonexistent in children with single ventricle anatomy. We aimed to report our experience with nicardipine in these patient populations.
Related Products
Historical Records: Mertansine | Paclitaxel | DBA-DM4 | Diplacine | MC-Val-Cit-PAB-Auristatin E | Mytoxin B | Tubulysin IM-2 | DBCO-PEG4-Val-Cit-PAB-MMAF | PNU-159682 | Triazolone HCl | Nicardipine Hydrochloride
